FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206569> ?p ?o ?g. }

• W4387206569 endingPage "e491" @default.
• W4387206569 startingPage "e491" @default.
• W4387206569 abstract "The purpose of this study was to assess the treatment outcome and the potential prognostic factors for patients with stage I-II nasal ENKTL treated with radiotherapy (RT) combined chemotherapy (CT).From July, 2005 to January, 2019, 118 eligible patients were retrospective included in the study. Among the 118 patients, 84 were male and 34 were female. The median age was 45 years (range: 14-77 years). According to the Ann Arbor staging system, 66 patients had stage I disease (Primary tumor invasion (PTI) was present in 29 patients), and 52 patients had stage II disease. B symptoms were observed in 61 patients. The Eastern Cooperative Oncology Group (ECOG) performance score was 0 to 1 in 88 patients. Cervical lymph node involvement was observed in 51 patients. The primary lesions were located in the nasal cavity in 92 cases and in the Waldeyer ring in 26 cases. Five patients had received RT followed by CT (RT + CT), 20 patients had received CT followed by RT (CT + RT), 90 patients had received CT followed by RT, again followed by CT (CT+RT+CT), and 3 patients had received concurrent chemoradiotherapy (CRT) (1 patient received CRT + CT, other 2 patients received CT+CRT+CT). Patients were irradiated with a median dose of 50 Gy (range, 24-61.2). All patients received chemotherapy, 91 received non-anthracycline-based chemotherapy, whereas 27 patients received anthracycline-based chemotherapy. The median number of courses of chemotherapy was four (range: 1-10). Patients were scored as having low-risk disease (n = 50), intermediate-risk disease (n = 60) or high-risk disease (n = 8) according to the prognostic index of natural killer cell lymphoma (PINK).Among the 118 patients, after initial therapy, the complete response (CR) rate was 82.2% (n = 97), and the partial response (PR) rate was 11.0% (n = 13). The stable disease (SD) rate was 2.5% (n = 3), and the progressive disease (PD) rate was 4.2% (n = 5). With a median follow-up of 43 months (range, 4-201) after irradiation, the 3-year PFS and OS were 76.9% and 82.9%, respectively. The 3-year OS rate was 75.0% for RT + CT, 70.0% for CT + RT, 87.1% for CT + RT+ CT, and 50.0% for CRT (P = 0.052). Three-year OS and PFS were 88.6% and 83.4%, respectively, for non-anthracycline-based chemotherapy regimen compared to 61.6% (P = 0.001) and 58.4% (P = 0.003), respectively, for the anthracycline-based chemotherapy regimen. Three-year OS and PFS were 84.0% and 79.0%, respectively, for patients receiving high-dose RT (≥50 Gy, n = 111) compared to 71.4% (P = 0.076) and 71.4% (P = 0.228), respectively, for low-dose RT (<50 Gy, n = 7). In multivariate analysis, adverse factors associated with OS in our study were chemotherapy regimen and response to RT and CT (P = 0.047, <0.001).Radiotherapy combined with chemotherapy reported promising response rate and a favorable survival for patients with stage I-II nasal ENKTL. Anthracycline-based chemotherapy regimen and no remission after RT and CT were adverse factors of OS." @default.
• W4387206569 created "2023-09-30" @default.
• W4387206569 creator A5006942799 @default.
• W4387206569 creator A5029030007 @default.
• W4387206569 creator A5040575560 @default.
• W4387206569 creator A5051538565 @default.
• W4387206569 creator A5060753195 @default.
• W4387206569 creator A5065048439 @default.
• W4387206569 creator A5084919966 @default.
• W4387206569 date "2023-10-01" @default.
• W4387206569 modified "2023-10-17" @default.
• W4387206569 title "Treatment Outcomes and Prognostic Factors of Chemotherapy Combined with Radiotherapy for Patients with Stage I-II Nasal-Type Natural Killer/T-Cell Lymphoma" @default.
• W4387206569 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1723" @default.
• W4387206569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785551" @default.
• W4387206569 hasPublicationYear "2023" @default.
• W4387206569 type Work @default.
• W4387206569 citedByCount "0" @default.
• W4387206569 crossrefType "journal-article" @default.
• W4387206569 hasAuthorship W4387206569A5006942799 @default.
• W4387206569 hasAuthorship W4387206569A5029030007 @default.
• W4387206569 hasAuthorship W4387206569A5040575560 @default.
• W4387206569 hasAuthorship W4387206569A5051538565 @default.
• W4387206569 hasAuthorship W4387206569A5060753195 @default.
• W4387206569 hasAuthorship W4387206569A5065048439 @default.
• W4387206569 hasAuthorship W4387206569A5084919966 @default.
• W4387206569 hasConcept C121608353 @default.
• W4387206569 hasConcept C126322002 @default.
• W4387206569 hasConcept C141071460 @default.
• W4387206569 hasConcept C146357865 @default.
• W4387206569 hasConcept C151730666 @default.
• W4387206569 hasConcept C167135981 @default.
• W4387206569 hasConcept C2776694085 @default.
• W4387206569 hasConcept C2776802502 @default.
• W4387206569 hasConcept C2778424827 @default.
• W4387206569 hasConcept C2779338263 @default.
• W4387206569 hasConcept C2779714933 @default.
• W4387206569 hasConcept C2780849966 @default.
• W4387206569 hasConcept C509974204 @default.
• W4387206569 hasConcept C530470458 @default.
• W4387206569 hasConcept C71924100 @default.
• W4387206569 hasConcept C86803240 @default.
• W4387206569 hasConcept C90924648 @default.
• W4387206569 hasConceptScore W4387206569C121608353 @default.
• W4387206569 hasConceptScore W4387206569C126322002 @default.
• W4387206569 hasConceptScore W4387206569C141071460 @default.
• W4387206569 hasConceptScore W4387206569C146357865 @default.
• W4387206569 hasConceptScore W4387206569C151730666 @default.
• W4387206569 hasConceptScore W4387206569C167135981 @default.
• W4387206569 hasConceptScore W4387206569C2776694085 @default.
• W4387206569 hasConceptScore W4387206569C2776802502 @default.
• W4387206569 hasConceptScore W4387206569C2778424827 @default.
• W4387206569 hasConceptScore W4387206569C2779338263 @default.
• W4387206569 hasConceptScore W4387206569C2779714933 @default.
• W4387206569 hasConceptScore W4387206569C2780849966 @default.
• W4387206569 hasConceptScore W4387206569C509974204 @default.
• W4387206569 hasConceptScore W4387206569C530470458 @default.
• W4387206569 hasConceptScore W4387206569C71924100 @default.
• W4387206569 hasConceptScore W4387206569C86803240 @default.
• W4387206569 hasConceptScore W4387206569C90924648 @default.
• W4387206569 hasIssue "2" @default.
• W4387206569 hasLocation W43872065691 @default.
• W4387206569 hasLocation W43872065692 @default.
• W4387206569 hasOpenAccess W4387206569 @default.
• W4387206569 hasPrimaryLocation W43872065691 @default.
• W4387206569 hasRelatedWork W1535958986 @default.
• W4387206569 hasRelatedWork W2053205102 @default.
• W4387206569 hasRelatedWork W2102871905 @default.
• W4387206569 hasRelatedWork W2376593068 @default.
• W4387206569 hasRelatedWork W2390264150 @default.
• W4387206569 hasRelatedWork W2390408846 @default.
• W4387206569 hasRelatedWork W2416632858 @default.
• W4387206569 hasRelatedWork W4220939315 @default.
• W4387206569 hasRelatedWork W4291189777 @default.
• W4387206569 hasRelatedWork W4308718010 @default.
• W4387206569 hasVolume "117" @default.
• W4387206569 isParatext "false" @default.
• W4387206569 isRetracted "false" @default.
• W4387206569 workType "article" @default.